´ëÇÑ¿ì¿ïÁ¶¿ïº´ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2021-09-03±³À°ÀÏÀÚ : 2021-09-03
±³À°Àå¼Ò : ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ ¹× ´ëȸÀǽÇ
±³À°ÁÖÁ¦ :
´ëÇÑ¿ì¿ïÁ¶¿ïº´ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À°ÁÖÃÖ±â°ü : ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑ¿ì¿ï.Á¶¿ïº´ÇÐȸ (ÀÌ»çÀåÁ¦)
´ã´çÀÚ : ´ëÇÑ¿ì¿ïÁ¶¿ïº´ÇÐȸ »ç¹«±¹
¿¬¶ôó : 02-3779-1250
À̸ÞÀÏ :
webmaster@thekasad.or.kr ±³À°Á¾·ù : Á¤½Å°Ç°ÀÇÇаú
Âü¼®¿¹»óÀοø : 90¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 13 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 80,000¿ø
ºñ°í »çÀüµî·Ï: Á¤È¸¿ø 5¸¸¿ø, ÁØȸ¿ø 3¸¸¿ø, ºñȸ¿ø 6¸¸¿ø, Æò»ýȸ¿ø ¸éÁ¦ ´çÀϵî·Ï: Á¤È¸¿ø 6¸¸¿ø, ÁØȸ¿ø 4¸¸¿ø, ºñȸ¿ø 8¸¸¿ø, Æò»ýȸ¿ø 1¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 09:30~09:50 Mood and personal traits as risk factors for physical illness È«Á¤¿Ï(Àͻ꺴¿ø)
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 09:50~10:10 Inflammation, physical illness, and depression ½Å»óÈ£(°í·ÁÀÇ´ë)
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 10:10~10:40 Metabolic syndrome and bipolar disorder °¿ø¼·(°æÈñÀÇ´ë)
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 10:55~11:15 Antidepressants: Minimalist vs. maximalist view ¹Ú¼º¿ë(°è¿äº´¿ø)
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 11:15~11:35 Antipsychotics: Evidence based treatment vs. potential treatment ¹Ú¿µ¹Î(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 11:35~12:05 Augmentation therapy: Focus on dopamine agonist & stimulant Á¤¸íÈÆ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 12:05~12:35 Anxiety & depression in the COVID pandemia ¿ì¿µ¼·(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 12:35~13:05 Benefits of Agomelatine treatment strategies Á¤Á¾Çö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 13:20~13:35 ¡®Irritability¡¯ as a symptom of depression for children and adolescents? À̹®¼ö(°í·ÁÀÇ´ë)
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 13:35~13:50 What can tell the differences between bipolar disorder and ADHD? ½É¼¼ÈÆ(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 13:50~14:05 Are there cognitive dysfunctions in bipolar disorder? ¿Õ¼º¹Î(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 14:05~14:30 What is the vascular depression hypothesis? ÀÌ°¼ö(Â÷ÀÇ°úÇдë)
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 14:30~14:50 Major depressive disorder ¿ì¿µ¼·(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 14:50~15:10 Bipolar disorder: Manic episode and mixed features ¹®Àº¼ö(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 15:10~15:40 Bipolar disorder: Depressive episode ÀÓÀº¼º(½Å¼¼°èÈ¿º´¿ø)
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 15:50~16:10 Navigating the world of ADHD medications ¾çÂù¸ð(¿ø±¤ÀÇ´ë)
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 16:10~16:30 Diagnosing and treating major depressive episodes with mixed features ½ÉÀÎÈñ(µ¿³²±Ç¿øÀÚ·ÂÀÇÇпø)
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 16:30~17:00 Long-acting injectable antipsychotics in bipolar disorder ±è°æ¹Î(±¹¸³³ªÁÖº´¿ø)
±³À°½Ã°£ 09-03 ´ëȸÀÇ½Ç 09:30~09:50 Suicide rate and risk factors in pandemic °ÇÑ°íÀººñ(±¹¸³³ªÁÖº´¿ø)
±³À°½Ã°£ 09-03 ´ëȸÀÇ½Ç 09:50~10:10 Immunity, suicide and COVID-19: A linking pathway Àå½ÂÈ£(¿ø±¤ÀÇ´ë)
±³À°½Ã°£ 09-03 ´ëȸÀÇ½Ç 10:10~10:40 Suicide prevention during COVID-19 ¿ÀÈ«¼®(°Ç¾çÀÇ´ë)
±³À°½Ã°£ 09-03 ´ëȸÀÇ½Ç 10:55~11:55 Mindfulness-based interventions for depression ±¸º»ÈÆ(¿µ³²ÀÇ´ë)
±³À°½Ã°£ 09-03 ´ëȸÀÇ½Ç 12:05~12:35 Importance of multifactorial condition management ¼ºÇü¸ð(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 09-03 ´ëȸÀÇ½Ç 12:35~13:05 Successful management of patient adherence ³²¹ü¿ì(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 09-03 ´ëȸÀÇ½Ç 13:20~13:40 Glutamatergic system ¼Û¹Î±Ô(¼º¸ð°ø°¨Á¤½Å°Ç°ÀÇÇаúÀÇ¿ø)
±³À°½Ã°£ 09-03 ´ëȸÀÇ½Ç 13:40~14:00 GABAergic system ±èÅÂÈñ(¿¬¼¼¿øÁÖÀÇ´ë)
±³À°½Ã°£ 09-03 ´ëȸÀÇ½Ç 14:00~14:30 Inflammatory system ÀÌÁ¤±¸(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 09-03 ´ëȸÀÇ½Ç 14:30~15:00 Overview and CBT approaches ±è¿ø(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 09-03 ´ëȸÀÇ½Ç 15:00~15:30 Family interventions Á¤¿µÀº(Á¦ÁÖÀÇ´ë)
±³À°½Ã°£ 09-03 ´ëȸÀÇ½Ç 15:50~16:10 PTSD and depression after trauma exposure À̺´Ã¶(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 09-03 ´ëȸÀÇ½Ç 16:10~16:30 Biological underpinnings of trauma and depression ±èÁö¼±(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 09-03 ´ëȸÀÇ½Ç 16:30~17:00 Treating depression of victims ±è¿øÇü(ÀÎÇÏÀÇ´ë)